Miami, New York City, St. Louis and Seattle will Host the Clinical Series in
the Fall
PLEASANTON, Calif., August 1 /PRNewswire/ -- Following the success of its
Spring seminar series, Mallinckrodt's (NYSE: MKG) Nellcor oximetry business
today announced the dates and locations of its Fall schedule. The seminars
will be held in Miami on September 26, New York City on September 27, St.
Louis on September 28, and Seattle on November 7. The conferences provide a
comprehensive overview of the latest advances in pulse oximetry and the future
of critical care medicine.
Prominent medical specialists Thomas G. Rainey, M.D., director of Critical
Care at Suburban Hospital, Bethesda, Maryland, and chairman of the Institute
for Healthcare Improvement Breakthrough Series on Cost Reduction and Outcomes
Improvement in Adult Intensive Care; and Arthur Combs, M.D., vice president of
Research and Development -- Respiratory, Mallinckrodt, lead the conference
sessions.
Meetings held earlier this year in Boston, Chicago, Atlanta, Houston and
Los Angeles attracted nearly 400 physicians, critical care nurses, and
respiratory care clinicians. Mallinckrodt's Nellcor oximetry business expects
similar numbers of attendees at the Fall series of events.
Session attendees explore issues and developments in pulse oximetry and
the use of advanced technology in critical care medicine. The seminar also
features an interactive discussion and demonstration of the latest Nellcor(R)
technology, the N-395 Pulse Oximeter. Equipped with Oxismart(R) XL Advanced
Signal Processing and SatSeconds(TM) Alarm Management, the N-395 is designed
to address the issues of motion and low perfusion. Over 11,000 units have
been sold since the N-395 was introduced in October 1999.
Healthcare professionals who would like additional information or who wish
to register for one of the upcoming seminars should call 1-800-OXIMETER or E-
mail knadeau@mullen.com.
About Mallinckrodt
Mallinckrodt Inc. is a global manufacturer and marketer of specialty
medical products designed to sustain breathing, diagnose disease and relieve
pain. Named one of America's most admired medical products and equipment
companies by Fortune magazine; Mallinckrodt does business in more than 100
countries. In fiscal 1999, combined net sales were $2.6 billion for
Mallinckrodt's respiratory, imaging and pharmaceutical product lines.
Mallinckrodt's Nellcor oximetry business is the world leader in pulse oximetry
with over 80 OEM and Licensing partners, 16 sensor choices, over 50 corporate
account and IHN purchasing contracts, and four generations of oximetry
technology. Based in St. Louis, Missouri, Mallinckrodt's website address is
http://www.mallinckrodt.com.
This news release contains forward-looking statements that involve risks
and uncertainties. These statements are based on current expectations; actual
results may differ materially. Among the factors that could cause actual
results to differ materially from those projected are the following: the
effect of business and economic conditions; the impact of competitive products
and continued pressure on prices realized by the company for its products;
constraints on supplies of raw materials used in manufacturing certain of the
company's products; capacity constraints limiting the production of certain
products; difficulties or delays in the development, production, testing, and
marketing of products; difficulties or delays in receiving required
governmental or regulatory approvals; market acceptance issues, including the
failure of products to generate anticipated sales levels; difficulties in
rationalizing acquired businesses and in realizing related cost savings and
other benefits; the effects of and changes in trade, monetary and fiscal
policies, laws and regulations; foreign exchange rates and fluctuations in
those rates; the costs and effects of legal and administrative proceedings,
including environmental proceedings and patent disputes involving the company;
difficulties or delays in addressing "Year 2000" problems in the company's
operations, or the inability of a major supplier or customer to continue
operations due to such problems; and the risk factors reported from time to
time in the company's SEC reports. The company undertakes no obligation to
update any forward-looking statements as a result of future events or
developments.
SOURCE Mallinckrodt Inc.
 back to top
Related links:
http://www.mallinckrodt.com
CONTACT:
Barbara Abbett of Mallinckrodt Inc.,
314-654-5230, barbara.abbett@mkg.com; or Joyce McMahon,
978-468-1155 ext. 1152, joyce.mcmahon@mullen.com, or Kara Nadeau,
978-468-1155 ext. 2146, knadeau@mullen.com, both of Mullen Public
Relations
|
